1. Home
  2. GURE vs LPTX Comparison

GURE vs LPTX Comparison

Compare GURE & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GURE
  • LPTX
  • Stock Information
  • Founded
  • GURE 2006
  • LPTX 2011
  • Country
  • GURE China
  • LPTX United States
  • Employees
  • GURE N/A
  • LPTX N/A
  • Industry
  • GURE Major Chemicals
  • LPTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • GURE Industrials
  • LPTX Health Care
  • Exchange
  • GURE Nasdaq
  • LPTX Nasdaq
  • Market Cap
  • GURE 9.5M
  • LPTX 11.1M
  • IPO Year
  • GURE 1992
  • LPTX N/A
  • Fundamental
  • Price
  • GURE $0.75
  • LPTX $0.28
  • Analyst Decision
  • GURE
  • LPTX Hold
  • Analyst Count
  • GURE 0
  • LPTX 1
  • Target Price
  • GURE N/A
  • LPTX N/A
  • AVG Volume (30 Days)
  • GURE 60.5K
  • LPTX 2.0M
  • Earning Date
  • GURE 08-13-2025
  • LPTX 08-14-2025
  • Dividend Yield
  • GURE N/A
  • LPTX N/A
  • EPS Growth
  • GURE N/A
  • LPTX N/A
  • EPS
  • GURE N/A
  • LPTX N/A
  • Revenue
  • GURE $13,919,011.00
  • LPTX N/A
  • Revenue This Year
  • GURE N/A
  • LPTX N/A
  • Revenue Next Year
  • GURE N/A
  • LPTX N/A
  • P/E Ratio
  • GURE N/A
  • LPTX N/A
  • Revenue Growth
  • GURE N/A
  • LPTX N/A
  • 52 Week Low
  • GURE $0.50
  • LPTX $0.22
  • 52 Week High
  • GURE $1.47
  • LPTX $4.79
  • Technical
  • Relative Strength Index (RSI)
  • GURE 60.43
  • LPTX 44.35
  • Support Level
  • GURE $0.69
  • LPTX $0.27
  • Resistance Level
  • GURE $0.75
  • LPTX $0.31
  • Average True Range (ATR)
  • GURE 0.07
  • LPTX 0.02
  • MACD
  • GURE 0.00
  • LPTX 0.00
  • Stochastic Oscillator
  • GURE 56.25
  • LPTX 38.33

About GURE Gulf Resources Inc. (NV)

Gulf Resources Inc is a holding company engaged in the manufacture and trade of bromine and crude salt, and natural gas; manufactures and sells chemical products used in oil and gas field exploration, oil and gas distribution, oil field drilling, wastewater processing, papermaking chemical agents and inorganic chemicals, and manufactures and sells materials for human and animal antibiotics. It operates in four segments: Bromine, Crude Salt, Chemical Products and Natural Gas. It derives maximum revenue from the Bromine segment which is commonly used in brominated flame retardants, fumigants, water purification compounds, dyes, medicines and disinfectants.

About LPTX Leap Therapeutics Inc.

Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.

Share on Social Networks: